Whole Blood Stimulation Assay as a Treatment Outcome Monitoring Tool for VL Patients in Ethiopia: A Pilot Evaluation

Table 2

Proportion of patients that produced levels above the calculated optimal cut-off values after SLA stimulation of a whole blood sample.

Analytes (cut-off value)	L. donovani			L. infantum
	D0; (%)	W1; (%)	EOT; (%)	D0; (%)	W1; (%)	EOT; (%)
IFN-γ (48.1 pg/ml)	4/13 (31)	10/13 (77)	13/13 (100)	4/13 (31)	10/13 (77)	13/13 (100)
TNF-α (25.4 pg/ml)	4/13 (31)	9/13 (69)	10/13 (77)	4/13 (31)	10/13 (77)	11/13 (85)
IP-10 (452.9 pg/ml)	3/13 (23)	11/13 (85)	12/13 (92)	3/13 (23)	9/13 (69)	12/13 (92)
IL-2 (20.0 pg/ml)	0/13 (0)	0/13 (0)	5/13 (38)	0/13 (0)	0/13 (0)	5/13 (38)
IL-10 (37.3 pg/ml)	5/13 (38)	5/13 (38)	4/13 (31)	3/13 (23)	5/13 (38)	5/13 (38)

D0: active moment, day zero; W1: first week of the treatment; EOT: end of treatment; : number of patients; %: percentage of positives patients that produce cytokines/chemokines.